Loading
In England and Wales a national audit now reports each year what share of people diagnosed with pancreatic cancer receive any treatment aimed at the cancer, how many are discussed by a specialist team and how many see a specialist nurse. The proposal is a national target for the treatment rate, published by hospital, so the trusts furthest behind are visible.
The National Pancreatic Cancer Audit, run by the National Cancer Audit Collaborating Centre, has published three State of the Nation reports (2024, covering patients diagnosed 2020 to 2021 in England and 2022 in Wales; 2025; and 2026, covering 2022 to 2023 in England and 2023 to 2024 in Wales), each with five recommendations, and reports performance indicators including multidisciplinary team discussion, clinical nurse specialist involvement, enzyme replacement prescribing and receipt of active treatment, with a data viewer for individual organisations. This is a placeholder for the gaps the UK and NHS page names in detail: the proportion receiving no active treatment, variation between trusts, the time from diagnosis to treatment, and the treatment rate in older and less fit patients. The idea is to attach a national target to the active treatment indicator, publish trust-level results with case-mix adjustment, and fund the multidisciplinary capacity (surgeons, oncologists, specialist nurses, dietitians) in the trusts below it. Pancreatic Cancer UK's campaigns (Don't Write Me Off; Unite Diagnose Save Lives 2025) make the same case.
Shares Pancreatic enzyme replacement by default: prescribe at diagnosis, audit the rate, and run the trial that settles survival, Enzyme replacement improves survival among patients with pancreatic cancer: Results of a population based study, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Pancreatic enzyme replacement by default: prescribe at diagnosis, audit the rate, and run the trial that settles survival, Enzyme replacement improves survival among patients with pancreatic cancer: Results of a population based study, Older and multimorbid patients are excluded and undertreated, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question and the tag pancreatic-evidence.
Shares A fast-track pathway from suspicion to treatment for pancreatic cancer in the NHS, measured from first scan to first treatment, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.